CervoMed to Participate in Upcoming Investor Conferences
CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Sidoti Virtual Micro Cap Conference on November 14 at 2:30 PM ET and the Stifel 2024 Healthcare Conference on November 19 at 3:00 PM ET. Both presentations will be available via webcast and accessible through CervoMed's website investor section.
CervoMed (NASDAQ: CRVO), una società in fase clinica che sviluppa trattamenti per disturbi neurologici legati all'età, ha annunciato la sua partecipazione a due conferenze per investitori in programma a novembre 2024. L'azienda presenterà al Sidoti Virtual Micro Cap Conference il 14 novembre alle 14:30 ET e al Stifel 2024 Healthcare Conference il 19 novembre alle 15:00 ET. Entrambe le presentazioni saranno disponibili in webcast e accessibili attraverso la sezione investitori del sito web di CervoMed.
CervoMed (NASDAQ: CRVO), una empresa en etapa clínica que desarrolla tratamientos para trastornos neurológicos relacionados con la edad, ha anunciado su participación en dos conferencias de inversores que se llevarán a cabo en noviembre de 2024. La compañía presentará en la Sidoti Virtual Micro Cap Conference el 14 de noviembre a las 2:30 PM ET y en la Stifel 2024 Healthcare Conference el 19 de noviembre a las 3:00 PM ET. Ambas presentaciones estarán disponibles a través de webcast y se podrán acceder en la sección de inversores del sitio web de CervoMed.
CervoMed (NASDAQ: CRVO), 노화 관련 신경 장애 치료제를 개발하는 임상 단계 회사가 2024년 11월에 열리는 두 개의 투자자 회의에 참가한다고 발표했습니다. 이 회사는 11월 14일 오후 2:30 ET에 Sidoti Virtual Micro Cap Conference에서 발표하고, 11월 19일 오후 3:00 ET에 Stifel 2024 Healthcare Conference에서도 발표할 예정입니다. 두 발표는 웹캐스트를 통해 제공될 예정이며, CervoMed 웹사이트의 투자자 섹션을 통해 접근할 수 있습니다.
CervoMed (NASDAQ: CRVO), une société en phase clinique développant des traitements pour des troubles neurologiques liés à l'âge, a annoncé sa participation à deux conférences d'investisseurs à venir en novembre 2024. L'entreprise présentera lors de la Sidoti Virtual Micro Cap Conference le 14 novembre à 14h30 ET et lors de la Stifel 2024 Healthcare Conference le 19 novembre à 15h00 ET. Les deux présentations seront disponibles en webcast et accessibles via la section investisseurs du site web de CervoMed.
CervoMed (NASDAQ: CRVO), ein Unternehmen in der klinischen Phase, das Behandlungen für altersbedingte neurologische Erkrankungen entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im November 2024 angekündigt. Das Unternehmen wird am 14. November um 14:30 Uhr ET auf der Sidoti Virtual Micro Cap Conference und am 19. November um 15:00 Uhr ET auf der Stifel 2024 Healthcare Conference präsentieren. Beide Präsentationen werden per Webcast verfügbar sein und sind über den Investorenbereich der CervoMed-Website zugänglich.
- None.
- None.
BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company’s Management will participate in the following investor conferences during the month of November:
Sidoti Virtual Micro Cap Conference
Format: Corporate presentation
Date: Thursday, November 14, 2024
Time: 2:30 PM ET
Webcast Link: click here
Stifel 2024 Healthcare Conference
Format: Corporate presentation
Date: Tuesday, November 19, 2024
Time: 3:00 PM ET
Webcast Link: click here
The webcast of the presentations will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.
About CervoMed
CervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with early-stage DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
FAQ
When is CervoMed (CRVO) presenting at the Sidoti Virtual Micro Cap Conference in 2024?
What time is CervoMed's (CRVO) presentation at the Stifel 2024 Healthcare Conference?
Where can investors watch CervoMed's (CRVO) investor conference presentations?
What investor conferences is CervoMed (CRVO) attending in November 2024?
